165 related articles for article (PubMed ID: 17853308)
1. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
Myers WA; Najarian D; Gottlieb AB
J Dermatolog Treat; 2006; 17(6):353-4. PubMed ID: 17853308
[TBL] [Abstract][Full Text] [Related]
2. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
[TBL] [Abstract][Full Text] [Related]
3. Delayed generalized inflammatory psoriasis flare during efalizumab treatment.
Martin B; Sánchez-Carazo JL; Pérez-Ferriols A; Oliver V; Alegre V
Br J Dermatol; 2009 Jul; 161(1):212-3. PubMed ID: 19438856
[No Abstract] [Full Text] [Related]
4. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
Balato A; La Bella S; Gaudiello F; Balato N
J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
[TBL] [Abstract][Full Text] [Related]
5. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report.
Bang B; Gniadecki R
Acta Derm Venereol; 2006; 86(5):456-7. PubMed ID: 16955198
[No Abstract] [Full Text] [Related]
6. Efalizumab-induced inflammatory polyarthritis: what are the implications?
Lyman J; Serebro L
South Med J; 2010 Apr; 103(4):357-60. PubMed ID: 20224509
[TBL] [Abstract][Full Text] [Related]
7. Case reports: practical experience with efalizumab in hand and foot psoriasis.
Cohen DJ; Scherschun L
J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
[TBL] [Abstract][Full Text] [Related]
8. [Efalizumab].
Descamps V
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
[TBL] [Abstract][Full Text] [Related]
9. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
Lowes MA; Turton JA; Krueger JG; Barnetson RS
BMC Dermatol; 2005 Aug; 5():9. PubMed ID: 16109173
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
[TBL] [Abstract][Full Text] [Related]
12. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
13. Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
[TBL] [Abstract][Full Text] [Related]
14. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
Leonardi C; Menter A; Hamilton T; Caro I; Xing B; Gottlieb AB
Br J Dermatol; 2008 May; 158(5):1107-16. PubMed ID: 18373710
[TBL] [Abstract][Full Text] [Related]
15. Efalizumab: a review of events reported during clinical trials and side effects.
Scheinfeld N
Expert Opin Drug Saf; 2006 Mar; 5(2):197-209. PubMed ID: 16503742
[TBL] [Abstract][Full Text] [Related]
16. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
[TBL] [Abstract][Full Text] [Related]
17. Exacerbation of psoriasis under efalizumab therapy.
Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
[TBL] [Abstract][Full Text] [Related]
18. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
19. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
20. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
Schön MP
Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
